Clinician’s Brief spotlights practical osteoarthritis pain management

CURRENT FULL VERSION: Clinician’s Brief has added another osteoarthritis-focused education item to its clinical content lineup with “Practical Advice on Managing Osteoarthritis Pain With Dr. Downing,” a sponsored partner podcast featuring Dr. Robin Downing, hosted by Dr. Beth Mollison, and backed by PRN Pharmacal. Based on the listing and source material, the conversation centers on the pain and inflammation associated with osteoarthritis and what clinicians can do about it in day-to-day practice. It also fits with the publication’s wider mobility and joint-health coverage, including partner podcast content on practical strategies that go beyond medications and supplements alone. (cliniciansbrief.com)

The timing fits a broader shift in veterinary medicine toward treating osteoarthritis as a chronic, actively managed pain condition rather than an inevitable part of aging. The 2022 AAHA Pain Management Guidelines for Dogs and Cats frame pain management as an evolving area of practice and recommend thorough assessment, regular monitoring, tailored pharmacologic plans, nonpharmacologic support, and strong client education. In other words, the profession has been moving toward systems-based OA care, not episodic symptom control. That same broader educational push now increasingly includes mobility preservation, rehab strategies, and day-to-day function as core parts of joint-health management. (aaha.org)

That backdrop matters because the canine OA toolkit has changed materially over the past few years. FDA approved Librela (bedinvetmab injection) in 2023 as the first monoclonal antibody approved for use in dogs, indicated for the control of pain associated with osteoarthritis. The agency said the drug showed effectiveness when at least two monthly doses were given 28 days apart, with pain assessed using the Canine Brief Pain Inventory. More recently, FDA also posted safety-related labeling changes for Librela in February 2025, underscoring that innovation in this category is being accompanied by continued post-market scrutiny and monitoring. (fda.gov)

At the same time, newer evidence is refining where these therapies may fit in practice. A 2025 Frontiers in Veterinary Science study compared bedinvetmab with meloxicam in client-owned dogs recruited through primary care practices in the UK, reflecting real-world management decisions in general practice. The paper also reinforces a point many clinicians already recognize: NSAIDs remain foundational in canine OA management, but they now sit within a wider menu of options that can include injectable biologics, rehab, nutrition, exercise modification, and adjunctive therapies. That wider menu is increasingly relevant not just for dogs but for cats too, as mobility experts continue to emphasize that feline obesity, indoor inactivity, and longer lifespans can all contribute to primary osteoarthritis and underrecognized declines in day-to-day function. (frontiersin.org)

Dr. Downing’s perspective is especially relevant in that multimodal context. In prior educational commentary for VCA and dvm360, she has emphasized that osteoarthritis treatment plans should be individualized and layered, with NSAIDs, supportive modalities, and ongoing reassessment used to improve function while managing risk. That aligns closely with AAHA guidance and suggests the Clinician’s Brief episode is part of a continuing industry-wide effort to make OA care more practical and protocol-driven for frontline teams. It also mirrors themes from other Clinician’s Brief mobility education featuring sports medicine and rehab specialists, where the focus has been on preserving movement and quality of life through strategies that extend beyond medication alone. (vcahospitals.com)

Why it matters: For veterinary professionals, this story is really about clinical execution. OA is common, chronic, and often under-recognized until mobility loss is obvious to the pet parent. Educational content that translates pain science into exam-room decisions can help practices build better screening, monitoring, and follow-up systems, especially for senior patients. It also supports more nuanced conversations with pet parents about expectations: OA treatment is usually long-term, multimodal, and adjusted over time based on response, comorbidities, tolerance, and quality-of-life goals. And because mobility concerns are not limited to classic canine arthritis cases, that same framework can help teams think more broadly about overweight cats, post-surgical patients, and pets with ligament or other orthopedic issues whose owners are primarily focused on keeping them active and comfortable. (aaha.org)

There’s also a business and risk-management layer. As the OA category expands, practices need clear protocols for case selection, informed consent, adverse-event monitoring, and recheck cadence. That applies whether a clinic leans on legacy NSAID therapy, newer anti-NGF products, or a combination approach. Sponsored educational content won’t answer every clinical question, but it can shape how quickly new frameworks reach general practice, particularly when it features a well-known pain specialist like Downing. It may also reinforce a more practical message many rehab clinicians have been making: mobility care often depends on integrating weight control, activity planning, home-environment changes, and rehabilitation support with drug therapy rather than treating medication as the whole plan. (cliniciansbrief.com)

What to watch: The next phase in canine OA management will likely center on how general practices integrate newer biologics with established multimodal care, while regulators, manufacturers, and clinicians continue to watch safety reporting, labeling updates, and comparative evidence. More broadly, expect continued emphasis on protocols that connect pain control with mobility support, rehab, weight management, and earlier recognition of OA in both dogs and cats. (fda.gov)